Patient Care

PharmaTher Receives US FDA Approval Goal Date for Ketamine

The Assigned FDA Approval Goal Date is June 4, 2025TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the…

10 months ago

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the…

10 months ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over…

10 months ago

Tilray Medical Launches Tilray Craft: Introducing High THC, High Terpene Genetics to the German Medical Cannabis Market

NEUMÜNSTER, Germany, March 11, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and…

10 months ago

TruBridge Announces Fourth Quarter and Full Year 2024 Results and Provides Initial 2025 Outlook

Revenue of $339.2 million for 2024 and $87.4 million in the fourth quarter Net loss of $23.1 million for 2024…

10 months ago

CLEW Announces the Launch of its Sepsis Virtual Unit to Enhance SEP-1 Compliance and Improve Patient Outcomes

BOSTON, March 10, 2025 /PRNewswire/ -- CLEW, a leading provider of AI-driven clinical surveillance solutions, today announced the launch of…

10 months ago

PerfectServe Launches 2025 Nurses of Note Awards Program with New Categories

Nominations open today and run through April 14; four grand prize winners to be recognized during National Nurses Week KNOXVILLE,…

10 months ago

Golden Helix Partners with the Danish Healthcare Regions to Drive Advancements in Genomic Medicine

BOZEMAN, Mont., March 10, 2025 /PRNewswire/ -- Golden Helix, a global leader in bioinformatics solutions for Next-Generation Sequencing (NGS) and precision…

10 months ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and…

10 months ago

BioLab Holdings, Inc. Announces Partnership with Real Collagen GmbH

Investment and Partnership will Allow Manufacturer to Create New Wound Care Products Using Fish Collagen PHOENIX, March 7, 2025 /PRNewswire/…

10 months ago